Study of Yili "Changqing" Pro-ABB Yoghurt in the Improvement of Human Gastrointestinal Tract System
Launched by INNER MONGOLIA YILI INDUSTRIAL GROUP CO., LTD · Sep 6, 2012
Trial Information
Current as of April 25, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Male or female subjects, 25-45 yrs;
- • 2. Non-specific and/or moderate constipation;
- • 3. Irregular or occasional gastrointestinal disorders (flatulence, gurgling, feeling heavy after eating, abdominal pain);
- • 4. Slow transit or irregular bowels movements (abnormal feces solidity, bowel movements decreased, e.g. every 2-3 days or less than 3 times per week).
- Exclusion Criteria:
- • 1. Diagnosed as chronic constipation;
- • 2. Treated gastrointestinal symptoms;
- • 3. Lactose Intolerance;
- • 4. Treatment by analgesic such as aspirin and paracetamol;
- • 5. Had laxatives or other remedies to promote digestion 2 weeks prior to the study start;
- • 6. Consuming dairy products or supplements containing pro/pre-biotic 10 days prior to the study start;
- • 7. Currently suffering from diarrhea.
Trial Officials
Ying An, Ph.D
Study Director
Inner Mongolia Hilo Industrial Group Co., Ltd
Donglian Cai
Principal Investigator
Changhai Hospital of Shanghai, Nutriology Dept.
Xinwang Gao
Principal Investigator
Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Geriatric Medicine Dept..
About Inner Mongolia Yili Industrial Group Co., Ltd
Inner Mongolia Yili Industrial Group Co., Ltd. is a leading Chinese enterprise specializing in the production and distribution of dairy products and related nutritional goods. Established in 1999, Yili has rapidly expanded its operations and product offerings, becoming a prominent player in the global dairy market. The company is committed to innovation, quality, and sustainability, leveraging advanced technology and rigorous research to enhance its product portfolio. Yili actively participates in clinical trials to explore the health benefits of its products, aiming to contribute to the advancement of nutritional science and improve public health outcomes. With a strong emphasis on consumer well-being and a dedication to corporate social responsibility, Yili continues to set industry standards and drive growth in the dairy sector.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Gucun, Baoshan District,, Shanghai, China
Chaoyang District, Beijing, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials